CN101563091A - 包含甲壳类动物胃石组分、碳酸钙的组合物及其用途 - Google Patents

包含甲壳类动物胃石组分、碳酸钙的组合物及其用途 Download PDF

Info

Publication number
CN101563091A
CN101563091A CNA200780045195XA CN200780045195A CN101563091A CN 101563091 A CN101563091 A CN 101563091A CN A200780045195X A CNA200780045195X A CN A200780045195XA CN 200780045195 A CN200780045195 A CN 200780045195A CN 101563091 A CN101563091 A CN 101563091A
Authority
CN
China
Prior art keywords
caco
chitin
matter
composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780045195XA
Other languages
English (en)
Chinese (zh)
Inventor
约西·本
阿米尔·萨吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ben Gurion University of the Negev BGU
Original Assignee
Ben Gurion University of the Negev BGU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben Gurion University of the Negev BGU filed Critical Ben Gurion University of the Negev BGU
Publication of CN101563091A publication Critical patent/CN101563091A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
CNA200780045195XA 2006-10-05 2007-10-07 包含甲壳类动物胃石组分、碳酸钙的组合物及其用途 Pending CN101563091A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL178495 2006-10-05
IL178495A IL178495A (en) 2006-10-05 2006-10-05 Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions

Publications (1)

Publication Number Publication Date
CN101563091A true CN101563091A (zh) 2009-10-21

Family

ID=39153987

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780045195XA Pending CN101563091A (zh) 2006-10-05 2007-10-07 包含甲壳类动物胃石组分、碳酸钙的组合物及其用途

Country Status (14)

Country Link
US (2) US20100098774A1 (enExample)
EP (1) EP2068891B1 (enExample)
JP (1) JP2010505818A (enExample)
CN (1) CN101563091A (enExample)
AU (1) AU2007303786B2 (enExample)
CA (1) CA2665141C (enExample)
CY (1) CY1114930T1 (enExample)
DK (1) DK2068891T3 (enExample)
ES (1) ES2439741T3 (enExample)
IL (1) IL178495A (enExample)
PL (1) PL2068891T3 (enExample)
PT (1) PT2068891E (enExample)
SI (1) SI2068891T1 (enExample)
WO (1) WO2008041236A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121351A (zh) * 2016-10-25 2019-08-13 艾玛菲克有限公司 用于治疗白血病的无定形碳酸钙

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257750B2 (en) * 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
CN101969962B (zh) 2007-10-22 2014-10-22 艾玛菲克有限公司 包含磷酸化氨基酸、合成的磷酸化肽和胃石蛋白的稳定的无定形碳酸钙
CA3056570C (en) * 2011-12-13 2022-04-19 Amir Sagi Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
RU2637019C2 (ru) 2012-08-07 2017-11-29 Аморфикал Лтд. Способ получения стабилизированного аморфного карбоната кальция
CN105007925A (zh) * 2013-02-11 2015-10-28 艾玛菲克有限公司 用于加速骨生长的无定形碳酸钙
CN103417635B (zh) * 2013-08-15 2015-05-20 张荣惠 接骨药
RU2740453C2 (ru) 2014-07-31 2021-01-14 Аморфикал Лтд. Неводные жидкие и полутвердые составы аморфного карбоната кальция
US12121538B2 (en) 2015-06-04 2024-10-22 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
IL256065B2 (en) * 2015-06-04 2024-04-01 Amorphical Ltd Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates
BR122022001962B1 (pt) * 2015-12-14 2023-05-16 Société des Produits Nestlé S.A. Composição nutricional sintética, seu uso, e derivado de ácido graxo
US11478011B2 (en) 2015-12-14 2022-10-25 Societe Des Produits Nestle S.A. Nutritional compositions and infant formula for promoting de novo myealination
EP4233907A3 (en) * 2015-12-14 2024-01-10 Société des Produits Nestlé S.A. Nutritional compositions and infant formulas to promote myelination in the brain
AU2017210259B2 (en) 2016-01-18 2022-11-03 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media
KR20250114395A (ko) 2016-01-18 2025-07-29 아모피컬 리미티드 신경, 근육 및 불임 질환 또는 병증의 치료를 위한 안정화된 무정형 탄산칼슘
CA3144221A1 (en) 2019-07-23 2021-01-28 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4199496A (en) * 1974-09-05 1980-04-22 Johnson Edwin L Process for the recovery of chemicals from the shells of crustacea
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US20060165784A1 (en) * 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
US20030077604A1 (en) * 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
JP2002205947A (ja) * 2000-12-11 2002-07-23 Chafflose Corporation 水虫治療薬
JP2005501845A (ja) * 2001-08-16 2005-01-20 メディカル リサーチ カウンシル キチン微小粒子およびそれらの医学的用途
JP2004081739A (ja) * 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
AU2003271016A1 (en) * 2003-09-17 2005-04-06 Bio-Wave Institute Of Suzhou Hi-Tech New District Corporation, Ltd. Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
WO2005115414A2 (en) * 2004-05-26 2005-12-08 Ben-Gurion University Of The Negev Research And Development Authority Orally-administrable compositions comprising stable amorphous calcium carbonate
AU2005296271A1 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121351A (zh) * 2016-10-25 2019-08-13 艾玛菲克有限公司 用于治疗白血病的无定形碳酸钙

Also Published As

Publication number Publication date
ES2439741T3 (es) 2014-01-24
US20130122117A1 (en) 2013-05-16
DK2068891T3 (da) 2014-01-13
IL178495A (en) 2014-12-31
PL2068891T3 (pl) 2014-03-31
US20100098774A1 (en) 2010-04-22
CA2665141A1 (en) 2008-04-10
CA2665141C (en) 2015-03-24
CY1114930T1 (el) 2016-12-14
WO2008041236A3 (en) 2009-05-14
EP2068891B1 (en) 2013-09-25
EP2068891A2 (en) 2009-06-17
PT2068891E (pt) 2013-12-27
AU2007303786B2 (en) 2012-07-26
WO2008041236A2 (en) 2008-04-10
AU2007303786A1 (en) 2008-04-10
JP2010505818A (ja) 2010-02-25
IL178495A0 (en) 2007-02-11
SI2068891T1 (sl) 2014-02-28
US8728533B2 (en) 2014-05-20

Similar Documents

Publication Publication Date Title
CN101563091A (zh) 包含甲壳类动物胃石组分、碳酸钙的组合物及其用途
EA012798B1 (ru) Фармацевтический состав, содержащий карбонат лантана (варианты)
EP0235417A1 (en) Inorganic mineral composition
CN101513484A (zh) 一种预防和治疗骨质疏松的药物组合物及其制备方法
WO2019134534A1 (zh) 一种e-10-羟基-2-癸烯酸在制备防治骨质疏松症的药品或保健品中的应用
JP2013231073A (ja) 生物学的平衡化合物の投与による病原体の減衰
JPH0563452B2 (enExample)
KR102225792B1 (ko) 에키노크롬 a를 유효성분으로 함유하는 폐경기 증후군의 치료 또는 예방용 약학적 조성물
CN103006693A (zh) 一种二维碳酸钙组合物
JPWO2006043336A1 (ja) 胃粘膜疾患の治療又は予防のための組成物
CN113425846A (zh) 一种改善骨密度、延缓骨及关节老化的配方
JP2010523563A (ja) 骨折および骨欠損の処置のためのハーブ製剤
CN105560857A (zh) 一种有改善消化道造影效果的中药制剂
CN112137087A (zh) 一种壮骨补钙的组合物、保健品及其制备方法
RU2076731C1 (ru) Средство и способ повышения неспецифической резистентности организма при заболеваниях внутренних органов
CN115251339B (zh) 一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法
CN101831004A (zh) 透明质酸锶盐系列化合物及其制备方法以及在医药中的应用
HU200933B (en) Process for producing pharmaceutical composition for profilacting and treating osteoporosis
CN110384241A (zh) 一组有助于骨健康的组合物及其制备方法
CN100479861C (zh) 硫酸软骨素胶囊剂和片剂的强化性添加剂及其制备方法
CN107982409B (zh) 一种治疗脊髓空洞症的中药组合物、丸剂及其制备方法
CN106173614A (zh) 一种具有增加骨密度功能的组合物及其制备方法
CN113712990A (zh) 一种组合物及其制备方法与应用
CN114366764A (zh) 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物
CN100542574C (zh) 股骨再生的药物及其制备工艺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20091021